Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pak Fah Yeow International Limited (0239.HK)
Wan Chai, HK
Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and other international territories. The company's operations are categorized into three distinct divisions: Healthcare, Property Investments, and Treasury Investments. Among its key offerings are medicated oils, such as white flower embrocation, along with various ointments and solutions for strain relief, including the floral-scented Fúzai 239 white flower embrocation. Beyond its primary healthcare focus, the firm also commits capital to diverse real estate assets, encompassing commercial, industrial, residential, and car park properties, and additionally provides advertising agency services. This enterprise, established in 1927, maintains its corporate headquarters in Wan Chai, Hong Kong.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.21% | +0.82% | -2.00% | +1.24% | +1.66% | +3.38% | +2.08% | +76.26% | +32.43% | -37.50% | +323.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-9.7% Q4'25: -10.2% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+16.0% Q4'25: +6.3% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+49.6% ★ Q4'25: +38.0% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+51.2% ★ Q4'25: +60.7% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+24.2% ★ Q4'25: +65.1% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.06× ★ Q4'25: 0.02× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-27 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-22 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-07 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wee Sean Gan | Executive Chairman & Chief Executive Officer | 8M | male |
| Cheng Hooi Gan | Executive Director | 2M | male |
| Fock Wai Gan | Executive Director | 2M | male |
| Gan Geok | Founder | — | male |
| Hung Kei Tsang ACCA AHKSA | Chief Financial Officer | — | male |
| Tai On Lo | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0239.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
